Tvardi Therapeutics, Inc.
TVRD
$27.74
$1.104.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 371.23% | 70.98% | 222.43% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 23.51% | -2.11% | 131.60% | ||
| Operating Income | -23.51% | 2.11% | -131.60% | ||
| Income Before Tax | 159.74% | -127.96% | -192.05% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 159.74% | -127.96% | -192.05% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 159.74% | -127.96% | -192.05% | ||
| EBIT | -23.51% | 2.11% | -131.60% | ||
| EBITDA | -23.58% | 2.12% | -132.28% | ||
| EPS Basic | 118.65% | -127.71% | -191.07% | ||
| Normalized Basic EPS | 118.65% | -127.73% | -191.06% | ||
| EPS Diluted | 62.94% | -127.71% | -191.07% | ||
| Normalized Diluted EPS | 118.19% | -127.73% | -191.06% | ||
| Average Basic Shares Outstanding | 220.28% | 0.11% | 0.33% | ||
| Average Diluted Shares Outstanding | 228.38% | 0.11% | 0.33% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||